IL270819B1 - Methods for treating chronic fasciitis - Google Patents

Methods for treating chronic fasciitis

Info

Publication number
IL270819B1
IL270819B1 IL270819A IL27081919A IL270819B1 IL 270819 B1 IL270819 B1 IL 270819B1 IL 270819 A IL270819 A IL 270819A IL 27081919 A IL27081919 A IL 27081919A IL 270819 B1 IL270819 B1 IL 270819B1
Authority
IL
Israel
Prior art keywords
treatment
methods
chronic pouchitis
pouchitis
chronic
Prior art date
Application number
IL270819A
Other languages
English (en)
Hebrew (he)
Other versions
IL270819A (en
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of IL270819A publication Critical patent/IL270819A/en
Publication of IL270819B1 publication Critical patent/IL270819B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL270819A 2017-05-26 2018-05-26 Methods for treating chronic fasciitis IL270819B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511832P 2017-05-26 2017-05-26
PCT/IB2018/053760 WO2018215995A1 (en) 2017-05-26 2018-05-26 Methods for the treatment of chronic pouchitis

Publications (2)

Publication Number Publication Date
IL270819A IL270819A (en) 2020-01-30
IL270819B1 true IL270819B1 (en) 2026-06-01

Family

ID=64395342

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270819A IL270819B1 (en) 2017-05-26 2018-05-26 Methods for treating chronic fasciitis

Country Status (10)

Country Link
US (2) US20200087401A1 (cg-RX-API-DMAC7.html)
EP (1) EP3630184A4 (cg-RX-API-DMAC7.html)
JP (2) JP7497159B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200011457A (cg-RX-API-DMAC7.html)
AU (1) AU2018274749B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019024875A2 (cg-RX-API-DMAC7.html)
CA (1) CA3065000A1 (cg-RX-API-DMAC7.html)
IL (1) IL270819B1 (cg-RX-API-DMAC7.html)
MX (1) MX2019014090A (cg-RX-API-DMAC7.html)
WO (1) WO2018215995A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3224280A1 (en) 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
WO2023163883A1 (en) * 2022-02-22 2023-08-31 First Wave BioPharma, Inc. Compositions and methods for treating pouchitis
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016105572A1 (en) * 2014-12-24 2016-06-30 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY
US20160340432A1 (en) * 2011-05-02 2016-11-24 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551593B1 (en) * 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160340432A1 (en) * 2011-05-02 2016-11-24 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
WO2016105572A1 (en) * 2014-12-24 2016-06-30 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAKEDA ET AL, PHASE 4 STUDY TO EVALUATETHE EFFICACY AND SAFETY OF VEDOLIZUMAB INTHE TREATMENT OF CHRONIC POUCHITIS, 6 April 2017 (2017-04-06) *

Also Published As

Publication number Publication date
CA3065000A1 (en) 2018-11-29
EP3630184A4 (en) 2021-03-17
EP3630184A1 (en) 2020-04-08
KR20200011457A (ko) 2020-02-03
US20230043949A1 (en) 2023-02-09
JP2020521761A (ja) 2020-07-27
AU2018274749B2 (en) 2025-05-22
MX2019014090A (es) 2021-01-08
RU2019143659A3 (cg-RX-API-DMAC7.html) 2021-10-08
IL270819A (en) 2020-01-30
US20200087401A1 (en) 2020-03-19
JP2024069230A (ja) 2024-05-21
JP7497159B2 (ja) 2024-06-10
BR112019024875A2 (pt) 2020-06-16
AU2018274749A1 (en) 2019-12-19
WO2018215995A1 (en) 2018-11-29
RU2019143659A (ru) 2021-06-28